'Dilbert' creator's desperate plea shines spotlight on alternative prostate cancer drug

The FDA-approved drug Pluvicto offers hope for advanced prostate cancer patients, but access barriers remain despite proven ...

Semaglutide showdown: Pills or shots—Which is right for you?

This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans

Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC.

The Inflammation Gap

Popular ideas about inflammation have lost touch with medical reality.

Opinion: Why Trump can do no wrong

Trump pardoned a convicted crypto billionaire, Changpeng Zhao, after Zhao’s company, according to reporting by The Wall ...
Santé log

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that its SOL-R registrational trial of ...

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal ...

ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis ...

Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025

Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of ...
The American Journal of Managed Care

Managed Care Considerations for Prescription Digital Therapeutics

Panelists discuss how managed care organizations can leverage prescription digital therapeutics as cost-reduction tools to ...
Taiwan News

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the first ...